The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| REGN | -29.29% | +20.63% | +3.82% | +3,004% |
| S&P | +18.13% | +110.72% | +16.08% | +1,716% |
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.75B | 0.9% |
| Gross Profit | $3.10B | -0.4% |
| Gross Margin | 82.47% | -1.1% |
| Market Cap | $59.59B | -48.6% |
| Market Cap / Employee | $3.95M | 0.0% |
| Employees | 15.1K | 12.3% |
| Net Income | $1.46B | 8.9% |
| EBITDA | $1.25B | -8.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.51B | 24.9% |
| Accounts Receivable | $5.69B | -6.9% |
| Inventory | 3.3K | 7.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.71B | 0.1% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 11.80% | -1.6% |
| Return On Invested Capital | 21.81% | -0.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.42B | 35.1% |
| Operating Free Cash Flow | $1.62B | 25.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 18.61 | 16.14 | 13.23 | 13.46 | -48.25% |
| Price to Book | 2.67 | 2.37 | 1.93 | 2.00 | -51.35% |
| Price to Sales | 5.71 | 5.01 | 4.01 | 4.23 | -52.04% |
| Price to Tangible Book Value | 2.78 | 2.46 | 2.01 | 2.09 | -51.04% |
| Price to Free Cash Flow TTM | 22.12 | 23.45 | 15.55 | 15.28 | -56.97% |
| Enterprise Value to EBITDA | 65.04 | 88.77 | 42.65 | 43.74 | -48.40% |
| Free Cash Flow Yield | 4.5% | 4.3% | 6.4% | 6.5% | 132.38% |
| Return on Equity | 16.0% | 16.0% | 15.3% | 15.2% | -11.52% |
| Total Debt | $2.94B | $2.70B | $2.71B | $2.71B | 0.06% |
Regeneron Pharmaceuticals stock got a shot in the arm after it announced a possible drug candidate for coronavirus.
Positive trial data unveiled at the American Society of Hematology conference makes these top stocks to watch in 2019.
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.
REGN earnings call for the period ending September 30, 2021.
REGN earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
